Key Market Indicator:
Ad-hoc news is mandatory information from listed companies that must be made available to investors. Depending on the occasion and content of the news, it can have an impact on the share price. The newsfeed covers a wide range of topics relevant to investor relations and is recommended as an important source of information before making an investment decision.
Fri, 13.03.2026
Liechtensteinische Landesbank / LLB
Vaduz, 13 March 2026. The LLB Group has published its complete Annual Report 2025. It contains comprehensive information concerning financial and non-financial aspects of the 2025 business year. In addition, the documents for the 34th ordinary General Meeting of Shareholders are dispatched.
The annual report for 2025 focuses on the successful furth [ … ]
Thu, 12.03.2026
Dexus Finance Pty Limited
Dexus (ASX: DXS)
ASX release
13 March 2026
Appendix 3C
Dexus today announced an Appendix 3C – Notice of Buy Back – daily trade notification.
The ASX release is available to download at www.dexus.com/dxs.
Authorised by Brett Cameron, General Counsel and Company Secretary of Dexus Funds Management Limited
For further information please contac [ … ]
Thu, 12.03.2026
Amrize Ltd
CHICAGO/ZUG, March 12, 2026 – Amrize (AMRZ) has published its Annual General Meeting (AGM) Invitation, Proxy Statement and Annual Report for Fiscal Year 2025.
Amrize’s Annual General Meeting will take place at the Theater Casino Zug, Artherstrasse 4, 6300 Zug, Switzerland on April 21, 2026 at 09:00 am CEST; doors open at 08:00 am CEST.
The docume [ … ]
Thu, 12.03.2026
Swiss Re Ltd
Ad hoc announcement pursuant to Article 53 LR
Annual Report 2025 presents Swiss Re's Group strategy and its business performance and risk assessment for 2025
Annual Report now includes the Sustainability Report
Invitation to 2026 Annual General Meeting (AGM) outlines the Board of Directors' proposals for shareholder vote
Swiss Re proposes to e [ … ]
Thu, 12.03.2026
BioVersys AG
Ad hoc announcement pursuant to Art. 53 LR
Basel, Switzerland. March 12, 2026, 7am CET.
Under the BioVersys and GSK collaboration agreement, AlpE clinical development advances with first patient dosed in Phase 2b trial within UNITE4TB, following completion of a Phase 2a in adults with drug-susceptible pulmonary TB (DS-TB) in combination with [ … ]
Thu, 12.03.2026
MindMaze Therapeutics Holding SA
MindMaze Therapeutics Appoints HealthTech Veteran Zach Henderson as CEO to Accelerate Global Commercial Scale
Former Rune Labs and Glooko executive to lead MindMaze’s next phase of growth, focusing on U.S. market expansion and the delivery of scalable, AI-driven neurorestorative care.
Geneva, Switzerland – March 12, 2026 – MindMaze Therapeutics H [ … ]
Thu, 12.03.2026
Zalando SE
Berlin, 12 March 2026 // Given the strong business momentum, the company’s robust fundamentals, its healthy balance sheet and strong cash flow generation, as well as management’s confidence in the future development, today the management board of Zalando SE decided to initiate a new share buy-back programme with the approval of the supervisory boar [ … ]
Thu, 12.03.2026
Kardex Holding AG
Kardex Holding AG / Key word(s): Annual Results
Kardex Holding AG: Financial Results 2025
12-March-2026 / 06:30 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
Thu, 12.03.2026
Accelleron Industries AG
Ad hoc announcements pursuant to Art. 53 LR
Accelleron delivers another year of outstanding growth and profitability
Continued momentum, strengthened market leadership, and strong financial performance in 2025
Revenues reached USD 1.263 billion, +23.5% year-on-year
Operational EBITA increased to USD 321.0 million (+22.6% YoY)
Net income incre [ … ]
Thu, 12.03.2026
PolyPeptide Group
Media release – ad hoc announcement pursuant to Art. 53 LR
PolyPeptide delivers strong revenue growth and marked improvement in profitability
Baar, 12 March 2026 – PolyPeptide Group AG (SIX: PPGN), a specialized global CDMO for peptide-based active pharmaceutical ingredients, today announced its annual results for 2025 and guidance for 2026:
Re [ … ]
